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FASTKD2 Nonsense Mutation in an Infantile
Mitochondrial Encephalomyopathy
Associated with Cytochrome C Oxidase Deficiency
Daniele Ghezzi,1 Ann Saada,2 Pio D’Adamo,3 Erika Fernandez-Vizarra,1 Paolo Gasparini,3
Valeria Tiranti,1 Orly Elpeleg,2 and Massimo Zeviani1,*
In two siblings we found a mitochondrial encephalomyopathy, characterized by developmental delay, hemiplegia, convulsions, asym-
metrical brain atrophy, and low cytochrome c oxidase (COX) activity in skeletal muscle. The disease locus was identiﬁed on chromosome
2 by homozygosity mapping; candidate genes were prioritized for their known or predicted mitochondrial localization and then se-
quenced in probands and controls. A homozygous nonsense mutation in the KIAA0971 gene segregated with the disease in the proband
family. The corresponding protein is known as fas activated serine-threonine kinase domain 2, FASTKD2. Confocal immunoﬂuorescence
colocalized a tagged recombinant FASTKD2 protein with mitochondrial markers, and membrane-potential-dependent in vitro mito-
chondrial import was demonstrated in isolated mitochondria. In staurosporine-induced-apoptosis experiments, decreased nuclear
fragmentation was detected in treated mutant versus control ﬁbroblasts. In conclusion, we found a loss-of-function mutation in
a gene segregating with a peculiar mitochondrial encephalomyopathy associated with COX deﬁciency in skeletal muscle. The
corresponding protein is localized in the mitochondrial inner compartment. Preliminary data indicate that FASTKD2 plays a role in
mitochondrial apoptosis.Mitochondrial disorders are clinical phenotypes associated
with abnormalities of the terminal component of aerobic
energy metabolism, i.e., oxidative phosphorylation (OX-
PHOS), a complex pathway linking cellular respiration to
adenosine triphosphate (ATP) synthesis. OXPHOS is car-
ried out in the inner mitochondrial membrane by the
mitochondrial respiratory chain (MRC). The MRC is com-
posed of a series of multiheteromeric enzymes resulting
from a dual genetic contribution, i.e., the nuclear and
themitochondrial genomes.Whereas the 13MRC proteins
encoded by mtDNA are all essential for OXPHOS, they
make up only a tiny fraction of the total number of pro-
teins involved in a functional MRC, most of which are in
fact nucleus encoded and imported into mitochondria.
As a consequence, mitochondrial disease can be due tomu-
tations in either mtDNA or nuclear DNA genes function-
ally related to MRC and OXPHOS.1 In fact, a huge number
of pathogenic mutations of mtDNA have been building up
in the last two decades, in association with a wide spec-
trum of clinical presentations. Albeit at a lesser rate, sub-
stantial progress has also been made in the characteriza-
tion of nuclear OXPHOS-related genes responsible for
mitochondrial syndromes.2
In addition to approximately 80 MRC structural sub-
units, OXPHOS nuclear genes encode a remarkable num-
ber of factors that control the formation, turnover, and
activity of MRC, including mtDNA biogenesis and expres-
sion, and their adaptation to tissue- and development-spe-
ciﬁc needs.3–5 The size of the mitochondrial proteome is
not precisely known, but the most recent studies have set
it up to more than 1400 entries.6,7 Each of these genesand proteins may be considered as a candidate for disease.
Therefore, it is not surprising that in spite of the tremen-
dous expansion of scientiﬁc and medical knowledge in
the ﬁeld, the genetic etiology of many mitochondrial clin-
ical syndromes still remains elusive, the mechanisms lead-
ing to disease are poorly understood, and the very function
of several factors involved in mitochondrial disorders is
not, or is at best partially, known. Approximately 60% of
biochemically deﬁned OXPHOS disorders still fail to get
diagnosed at the molecular level. To identify additional
nuclear genes that cause mitochondrial disease pheno-
types, we have embarked on a systematic, genome-wide
linkage-analysis project based on homozygosity mapping
of consanguineous multiplex families characterized by
mitochondrial recessive traits.
The family reported in this paper (Figure 1) is composed
of ﬁrst-cousin parents of Bedouin origin, with an offspring
of seven siblings, two of whom are affected by a peculiar,
early-onset encephalomyopathy.
Patient II-1, a female, was born at term after an unevent-
ful pregnancy by caesarean section due to nonprogression
of labor. Birth weight was 3800 grams. Bilateral congenital
hip dislocation was managed by abduction splinting.
Marked irritability and inconsolable cry were noted since
birth. Nonetheless, social and motor development was
reported as normal until 7 months of age. At that time,
she suffered from febrile illness and developed refractory
generalized tonic-clonic convulsions. Because atypical
pneumonia was suspected, she was treated with oral eryth-
romycin. Brain MRI examination disclosed generalized
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Figure 1. Pedigree and Haplotypes
Filled symbols indicate affected individuals. Each haplotype is indicated by a distinct color.her epileptic disease persisted, the psychomotor develop-
ment was markedly delayed, and left side hemiplegia en-
sued, with facial-nerve involvement. Brain CT scan per-
formed at 5 yr of age revealed severe atrophic changes on
the right hemisphere (Figure 2B). Because of ﬁxed contrac-
tures, the hip and ankle tendons were surgically released at
7 yr of age. Echocardiography, abdominal ultrasound,
blood count, and liver and renal functions were repeatedly
normal and plasma lactate was mildly increased (2.4–3.2
mM in different samples; normal values [n.v.] < 1.8 mM).
At 14 yr she obeyed simple commands in two languages,
could recognize colors, and had a 20 word vocabulary. She
could sit herself up and move herself relatively smoothly
along the ﬂoor while sitting, but was never able to stand
or walk. Her hearing was intact but the eyesight was im-
paired because of bilateral optic atrophy. She had left spas-
tic hemiparesis; on the right side the muscle tone was
decreased with reduced strength (3/5). Myoclonic and ge-
lastic seizures were partly controlled by carbamazepine,
valproate, and clonazepam. The EEG revealed bilateral ep-
ileptic activity, which was more prominent over the left
hemisphere. Biochemical assays were ﬁrst performed in
isolated mitochondria at Hadassah-Hebrew University
Medical Center in Jerusalem, Israel. As shown in Table 1,
the speciﬁc activity of cytochrome c oxidase (COX) was re-
duced to 21% of the control mean (3.1 nmoles/min/mg
versus a control mean of 14.8 5 3.6). The activities of416 The American Journal of Human Genetics 83, 415–423, Septemthe other MRC complexes, as well as that of the pyruvate
dehydrogenase complex (PDHc), were within the control
range. The respiratory-chain activities were measured 2 yr
later in the muscle homogenate by a second laboratory,
at the Istituto Neurologico ‘‘Carlo Besta’’ in Milan, Italy.
Again, the activity of COX, normalized to that of citrate
synthase (CS), was severely reduced, to 14% of the control
mean, while the activities of complex II and III were in the
lower limit of the normal or just below it (Table S1 available
online). The activity of complex I could not be measured
because of the scarcity of the material. In spite of the iso-
lated COX defect detected inmuscle homogenate, no gross
abnormality of COX and succinate dehydrogenase (SDH)
histochemical reactions were reported in muscle, and the
trichrome Gomori stain was normal. The activities of all
MRC complexes were normal in cultured skin ﬁbroblasts
(Table S1).
Patient II-6, the 6th child of the couple, was born at term,
with a birth weight of 4150 gr. His early development was
uneventful, and at 10 months he could sit himself up and
crawl freely. After a febrile gastroenteritis at 1 yr of age, the
patient experienced subacute neurological deterioration
with muscle hypotonia and extrapyramidal movements,
mainly on the left limbs. BrainMRI disclosed increased sig-
nal intensities on the left nucleus caudatus, globus pal-
lidus, and crus cerebri. The lateral ventricles and the basal
cysternae were of normal size (Figure 2C). A convulsiveber 12, 2008
disorder, ﬁrst noted at around one year, became refractory
to treatment at the third year of life. The patient went into
prolonged periods of status epilepticus; the EEG disclosed
ﬂattening of activity over the right hemisphere and tripha-
sic peaked waves over the left hemisphere. A brain CT scan
at 30 months revealed generalized and white-matter atro-
phy, more pronounced on the left basal ganglia, with bilat-
eral dilatation of the ventricles and basal cysternae
Figure 2. Brain Imaging
(A) Magnetic resonance imaging (MRI) T1-
weighted sequence on a transverse section
of supratentorial brain of patient II-1 at
disease onset (7 months of age).
(B) Computerized tomography (CT) scan of
the brain in patient II-1 at 5 yr.
(C) MRI T2-weighted sequence on a trans-
verse section of supratentorial brain in
patient II-6 at disease onset (1 yr of age).
(D) CT scan of the same brain section in
patient II-1 at 30 months.
Table 1. Biochemical Assays on Pt II-1 Muscle Mitochondria
Enzyme
Specific
Activity Pt II-1
Control
Mean5 SD %
Citrate Synthase mmol/min/mg 1.4 2.125 0.37 66
Succinate-ubiquinone
reductase
nmol/min/ng 56 775 15 73
Succinate dehydrogenase nmol/min/ng 206 3275 52 63
NADH-ferricyanide
reductase
mmol/min/mg 2.7 4.655 1.02 58
NADH-cyt. c
oxidoreductase
nmol/min/mg 445 5865 186 76
Succinate-cyt. c
oxidoreductase
nmol/min/mg 251 3335 100 75
Cytochrome c oxidase mmol/min/mg 3.1 14.85 3.6 21
Mg ATPase with DNP pmol/min/mg 888 7215 203 123
PDHc nmol/min/mg 81 805 24 101
(Figure 2D). At four years, he was
bed-ridden with neither communica-
tion nor any voluntary activity. There
was bilateral optic atrophy and stra-
bismus. His general muscle tone was
decreased with hyperreﬂexia and dys-
tonic posturing. The gag reﬂex was
weak and he was fed via gastrostome.
He had two episodes of deep-vein
thrombosis at sites of central-line
catheters, but blood coagulation
screen was negative. Echocardiogra-
phy, abdominal ultrasound, blood
count, blood gases, liver and renal
function tests, urinary organic acids,
plasma very-long-chain fatty acids,
plasma lactate, and amino acid levels
were normal. CSF lactate was in-
creased to 3.8 mM (n.v. < 1.8 mM),
and the activity of COX in his lymphocytes was reported
as markedly decreased. No other biological material is
available for this patient. The parents gave informed con-
sent to a biochemical and genetic screening according to
the Ethical Committee of Hadassah University Hospital,
Jerusalem, Israel. Blood samples were collected from par-
ents and all seven siblings of the family; DNAwas extracted
by standard methods. However, 2 yr ago we lost contact
with the family; therefore, we are currently unable to
give an updated follow-up of the probands.
Depletion of mtDNA and mtDNA large-scale rearrange-
ments were ruled out in skeletal muscle of patient II-1 by
real-time PCR8 and long-PCR analysis,9 respectively. Path-
ogenic mtDNA point mutations were also excluded by
sequence analysis of the entire mtDNA molecule10 from
skeletal muscle of the same patient.
A nuclear-genome-wide search was performed with the
ABI PRISM Linkage Mapping Set v.2.5 (Perkin Elmer, USA),
characterized by over 375 markers that deﬁne a 10 cM res-
olution human index map. PCR reactions with ﬂuores-
cently labeled primers were run under the conditions
suggested by the supplier. An aliquot of each PCR reaction
was run on an ABI PRISM 3100 DNA sequencer, and results
were processed by GENEMAPPER software. Statistical
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analysis was performed on the basis of an autosomal-reces-
sive disease with complete penetrance. Multipoint para-
metric linkage analysis was performed with SIMWALK2
2.91.11 The linkage analysis in the family gave a pairwise
lodmax score of 2.428 on D2S1338. A region with a LOD
score of ~2 is located between recombinant markers
D2S326 and D2S396 on chromosome 2q31-q36 (Figure S1,
available online). No other genomic region gave positive
lod scores by linkage analysis, suggesting that the 2q31-
q36 contained the responsible gene.
Haplotype reconstruction revealed a homozygous condi-
tion caused by identity-by-descent alleles in the affected
individuals (Figure 1). Because of their biochemical and
clinical features, we assumed that the responsible protein
was likely to be involved in mitochondrial metabolism
and be targeted to mitochondria.
The D2S326-D2S396 interval contains 382 gene entries,
some of which encode proteins that are known to target to
mitochondria. Other genes within this interval encode un-
known polypeptides that score high when analyzed with
dedicated prediction softwares for mitochondrial target-
ing, including MitoProt, TargetP, and PSORT-II. Sequenc-
ing of coding regions of 14 such genes (Table S2) failed to
reveal disease-segregating mutations, with the exception
of a homozygous missense mutation in the gene encoding
BCS1L, an assembly factor ofMRC complex III (CIII).12 The
mutation predicts a p.D210N amino acid change in a con-
served region of the BCS1L protein. However, the presence
of an isolated defect of complex IV (CIV) rather than CIII
in the muscle of patient II-1, the absence of an assembly
defect of CIII in either muscle or ﬁbroblasts (Figures S2),
and the detection of the p.D210N mutation in one out
of 240 chromosomes from Italian control samples cast
doubts about its pathogenic role. We then sequenced the
exons and the intron-exon junctions of an anonymous
gene entry (KIAA0971; primer sequences are available
upon request) encoding a protein with a high score for mi-
tochondrial targeting. The KIAA0971 cDNA (NM_014929)
corresponds to a gene spanning 27 kb and organized in 12
exons. The open reading frame (ORF) of KIAA0971 predicts
an amino acid sequence that contains a Fas-activated ser-
ine-threonine (FAST) kinase domain (NP_055744) and is
therefore known as FASTKD2, for FAST kinase domain pro-
tein 2 (MIM *606965). However, the human FASTKD2 N
terminus contains two potential translation-initiation me-
thionine residues, at positionþ1 andþ17 (M1, M17); both
M1 and the sequence betweenM1 and K16 are absent in all
of the nonhuman species in which FASTKD2 is present,
i.e., mammals and birds, including the closest living hu-
man relatives, e.g., Pan troglodytes and Pongo pygmaeus,
whereas M17 and the rest of the protein sequence are
both conserved (Figure S3A). For instance, in both Pan trog-
lodytes and Pongo pygmaeus, the potential predicted se-
quence corresponding to M1–M17 is identical to the hu-
man sequence, except that isoleucine is present at the
apparent amino acid position 1 instead of methionine,
whereas the methionine at position 17 is conserved418 The American Journal of Human Genetics 83, 415–423, Septem(Figure S3B). Taken together, these observations strongly
suggest that in humans as in other species, the ‘‘true’’
FASTKD2 protein starts from M17 rather than from M1.
Moreover, when mitochondrial-targeting prediction soft-
wares are used, the sequence starting at the alleged M1 res-
idue scores relatively high for mitochondrial targeting, but
that from M17 scores much higher (Mitoprot 72% versus
91%; TargetP 43% versus 76%). Therefore, we considered
the sequence starting fromM17 as the bona ﬁde physiolog-
ical human KIAA0971-encoding protein; it is hereafter
referred to as FASTKD2 and consists of 694 amino acid res-
idues, instead of the potentially translatable 710 residues.
According to the nucleotide numeration of NM_014929,
and considering the ATG encoding M17 as the translation
initiation codon, we found a homozygous c.1246C/T
nucleotide transition in both patients, whereas the two
parents were heterozygous (Figures 3A). The c.1246C/T
change determines the conversion of a CGA triplet, encod-
ing R416, into a TGA termination codon. This is by deﬁni-
tion a deleterious change (R416X) predicting the synthesis
of a prematurely truncated protein, missing the 278/694
C-terminal amino acid residues (Figure 3B). The mutation
was absent in 240 control alleles. The missing portion of
the mutant KIAA0971 protein sequence contains two pre-
dicted transmembrane domains (403–421 and 482–500
amino acid residues), as well as the FAST kinase domain.
Whereas the function of FASTKD2 is presently unknown,
previous work showed FAST to be anchored to the outer
face of the outer mitochondrial membrane, from where it
plays an inhibitory role in the activation of the Fas-depen-
dent apoptotic cascade.13 In order to establish experimen-
tally the subcellular localization of FASTKD2, a sequence
encoding a hemagglutinin (HA) tag of the inﬂuenza virus
was added in frame at the 30 end of the KIAA0971 ORF en-
coding FASTKD2, and the modiﬁed cDNA was inserted
into pCDNA3.2 (Invitrogen), a mammalian expression
vector. This construct was then transfected by electropora-
tion in COS7 cells and HeLa cells. After 24 hr, cells were
incubated with a monoclonal anti-HA and a polyclonal
anti-mtSSB (mitochondrial single-strand-DNA binding
protein) antibody. Immunoﬂuorescence images were ac-
quired with a confocal microscope (Biorad). As shown in
Figure 4, the FASTKD2HA-speciﬁc immunoﬂuorescence
pattern obtained with the anti-HA antibody coincided
with that of mtSSB, a mitochondrion-speciﬁc protein.
This result demonstrates that FASTKD2HA targets to mito-
chondria. Mitochondria are double-membrane organelles;
therefore, mitochondrial proteins can be localized in the
outer mitochondrial membrane (OMM), in the mitochon-
drial intermembrane (MIM) space, or in the inner mito-
chondrial compartment (IMC), consisting of the inner
mitochondrial membrane (IMM) and the mitochondrial
matrix (MM). Translocation into the IMC is an energy-
dependent process requiring bothATP and amitochondrial
membrane potential (DJ).14 For demonstration of active
mitochondrial import into the IMC, [35]S-radiolabeled
in vitro-translated FASTKD2, obtained with the TNT Quickber 12, 2008
Figure 3. FASTKD2 Features
(A) Sequence analysis of exon 7 of KIAA0971 showing the c.1246C/T change in patient II-1 (homozygous T), her father (heterozygous
C/T), and a control (homozygous C).
(B) Schematic structure of FASTKD2 protein. TP indicates a predicted cleavage site; TM indicates two putative transmembrane domains.
A red arrow indicates the position of the R416X mutation.
(C) Quantitative real-time PCR of FASTKD2 mRNA relative to GAPDH mRNA in different mouse tissues. The relative amount of FASTKD2/
GAPDH mRNA in muscle was taken as reference. Errors bars indicate the standard deviation (5 SD).Coupled Transcription/Translation Systems (Promega),
was incubated for 45 min at 37C with freshly prepared
HeLa-cell mitochondria energized by the addition of ATP
in the presence or absence of 20 mM valinomycin.15
After incubation, some samples were treated with pro-
teinase K (PK), with or without the previous addition of
PMSF, an inhibitor of PK, and/or Triton X-100, a detergent
that disrupts membranes. All samples were loaded into
SDS-PAGE; after ﬁxation in 10% acetic acid and 25% iso-
propanol, the gel was washed for 20 min in Amplify re-
agent (Amersham) and layered onto a phosphorimaging
screen (Biorad). After overnight exposure, autoradiography
was carried out in a Molecular Imager apparatus (Biorad).
Upon exposure to freshly prepared energized mitochon-
dria, two radiolabeled bands were visualized (Figure 4D),
a larger band corresponding to the full-length in vitro-
translated FASTKD2 and a shorter one corresponding toThe Americana mature protein species lacking an N-terminal mitochon-
drial target sequence. A potential cleavage site of the 79
kDa FASTKD2 precursor protein by the mitochondrial ma-
trix protease (MMP) is present between M52 and Q53 and
predicts the mature imported protein from the FASTKD2
precursor to be composed of 642 amino acid residues for
a MW of approximately 73 kDa. The two bands shown in
lane 2 correspond nicely to the size of either FASTKD2 pro-
tein species. Treatment with PK determined the complete
digestion of the upper band in intact mitochondria,
whereas a substantial amount of the lower band was left
intact, as expected to occur for a protein species imported
into, and protected by, the IMC. This digestion is speciﬁc
and can be blocked by the addition of PMSF. After treat-
ment of the mitochondrial membranes with Triton X-100,
exposure to PK determined the complete digestion of
both protein species, again indicating that the shorterJournal of Human Genetics 83, 415–423, September 12, 2008 419
Figure 4. Immunofluorescence and In Vitro Import Assay
(A) Immunofluorescence specific to mtSSB.
(B) Immunofluorescence specific to FASTKD2HA.
(C) Merge. All images were taken in COS7 cells 24 hr after FASTKD2HA transfection.
(D) Import assay on isolated HeLa cell mitochondria. Lane 1, in vitro-translated FASTKD2; lane 2, FASTKD2 þ mitochondria; lane 3,
FASTKD2 þ mitochondria þ PK; lane 4, FASTKD2 þ mitochondria þ PK þ PMSF; lane 5, FASTKD2 þ mitochondria FASTKD2 þ PK þ Triton
X-100; lane 6, FASTKD2 þ mitochondria þ valinomycin; and lane 7, FASTKD2 þ mitochondria þ valinomycin þ PK.polypeptide was located inside the IMC of the organelle. As
reported for other mitochondrial IMC proteins, the import
process was dependent on the presence of a mitochondrial
proton-motive force (DJ), because it was blocked by treat-
ment of the mitochondrial suspension with valinomycin,
an ionophore drug that dissipates DJ. These results dem-
onstrate that FASTKD2 is indeed imported into the IMC
through the DJ-dependent TOM-TIM import machinery,
which targets proteins to either the IMM or the MM.16
The presence of two predicted transmembrane domains
suggests that FASTKD2 is anchored to the IMM, and the
full protection from PK digestion indicates that it may
project toward the IMC.
Electronic data from arrays available in public databases
(Genecards) shows that FASTKD2 is ubiquitously expressed.
To measure FASTKD2 gene expression experimentally,
we created speciﬁc primers for the mouse ortholog
(NM_172422). ThenweextractedRNA fromdifferentmouse
tissues, and ﬁrst-strand cDNA was synthesized by standard
methods. We analyzed by real-time PCR the abundance of
the FASTKD2 transcript, normalized via the GAPDH tran-
script as reference. FASTKD2 transcript was expressed ubiq-
uitously, but in variable amounts from tissue to tissue, with
skeletalmuscle<heart%kidney< liver%brain (Figure3C).420 The American Journal of Human Genetics 83, 415–423, SeptemBecause nuclear genes coding for assembly factors of
COX, such as SURF-1, are known to cause CIV deﬁciency,
a role for FASTKD2 in COX assembly was evaluated by
blue-native gel electrophoresis (BNGE)-western-blot analy-
sis.17 However, we failed to demonstrate abnormality in
the assembly status and abundance of COX by using an
anti-COX1 antibody complex, in muscle of patient II-1
(Figure S2). Therefore, whether the COX defect is a direct
and speciﬁc consequence of, or is rather part of a more
general mitochondrial dysfunction induced by, the abol-
ishment of FASTKD2 remains an open issue for future
investigation.
The presence of a FAST domain in FASTKD2 and the in-
volvement of FAST in the apoptotic process prompted us to
evaluate nuclear fragmentation, taken as an index of apo-
ptotic response,18 in mutant versus control ﬁbroblasts
incubated with 1 mM staurosporine for 3 hr (Figure 5A).
Staurosporine, a potent protein kinase C inhibitor, is
known to induce apoptosis through a mitochondria-medi-
ated pathway19 and to cause oxidative stress throughmito-
chondrion-generated ROS in several cells.20 As shown in
Figure 5B, the percentage of fragmented nuclei in mutant
cells was signiﬁcantly lower than that of control cells
(Chi-square value ¼ 0.003). This result suggests a speciﬁcber 12, 2008
Figure 5. Staurosporine-Induced Apoptosis
(A) Hoechst staining of fibroblasts before and after staurosporine treatment. Red arrows indicate cells with fragmented nucleus.
(B) Quantification of cells with fragmented nucleus in control (Ct) and patient (Pt II-1) fibroblasts.
(C) Immunofluorescence images of COS7 cells 48 hr after FASTKD2HA transfection.role of FASTKD2 in the regulation of mitochondrial apo-
ptosis, because it does not seem to depend upon the
activity of the respiratory-chain complexes that were all
in the normal range in mutant ﬁbroblasts. In support of
this hypothesis stands the observation that overexpression
of recombinant FASTKD2HA in HeLa or COS7 cells consis-
tently led to shrinkage of the cell body, followed by nuclear
fragmentation and eventually apoptotic death (Figure 5C).
As a consequence, we were unable to generate stably over-
expressing FASTKD2HA cell lines. Whether this drastic ef-
fect is due to a speciﬁc function of FASTKD2, or to a generic
toxic effect due to damage of the inner mitochondrial
membrane, remains to be elucidated.
The clinical andMRI ﬁndings of the FASTKD2-associated
disease are rather unusual for mitochondrial disorders.
Combination of hemiplegia and epilepsy may be reminis-
cent of mitochondrial encephalomyopathy with lactic ac-
idosis and stroke-like episodes (MELAS, MIM #540000),21The Americanbut other features were missing, including RRF and lactic
acidosis. Other signs were peculiar of this syndrome and re-
sembled some key features of Rasmussen’s encephalopa-
thy, an allegedly immunological condition characterized,
like our probands, by infantile onset, intractable epilepsy,
emispheric atrophy with dilatation of the ipsilateral ventri-
cle system, and hemiparesis with a slowly progressive,
relentless course.22 However, we failed to identify muta-
tions in the KIAA0971 sequence in ﬁve consecutive pa-
tients with Rasmussen’s encephalopathy, suggesting that
the KIAA0971-associated syndrome is a genetic condition
that phenocopies but does not account for sporadic Ras-
mussen’s encephalopathy.
In conclusion, we found a previously unreported gene
mutated in a peculiar mitochondrial COX-defective ence-
phalomyopathy. We demonstrated that the responsible
protein, FASTKD2, is localized in the IMC, where it may
play a still-unknown role in apoptosis. Although FASTKD2Journal of Human Genetics 83, 415–423, September 12, 2008 421
is not directly involved in COX assembly, its ablation is in-
deedassociatedwithCOXdeﬁciency in skeletalmuscle. The
elucidation of the function of FASTKD2 is made difﬁcult by
the likely rarity of the clinical condition linked to its disrup-
tion (to our knowledge, this is theﬁrst and so far only family
with a FASTKD2mutation) and by the difﬁculty to establish
cell lines stably expressing recombinant FASTKD2HA. In ad-
dition, FASTKD2 seems to be present only inmammals and
birds, whereas no orthologs can be found in other animals,
plants, and lower eukaryotes. This prevents the possibility
to create models in user-friendly organisms such as yeast,
worm, or ﬂy. The restriction of FASTKD2 to relatively recent
classes of animals, notably those endowed with homeo-
thermy,may suggest a role for FASTKD2 in the ﬁnely-tuned
regulationof heathproductionbymitochondria. Theuse of
siRNA in cell culture, and the creationof amurine knockout
model for the FASTKD2gene,which is underway inour lab-
oratory, will help clarify the function of this new, elusive
component of the IMC and give a mechanistic interpreta-
tion to the mitochondrial syndrome affecting humans.
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